IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas
General Montana
•
November 16, 2026
•
Single-arm extension cohort of approximately 90 refractory GEP-NEC patients to support potential accelerated approval, with ORR by BICR as the primary endpointRandomized Phase 3 trial in multiple refractory NEC subtypes, including GEP-NEC and LC-NEC, is planned to support full approval,…
Source: Missoulian MT | https://missoulian.com/search/?f=rss&t=article&l=50&s=start_time&sd=desc - Read Original
Discussion (0)
Please log in to post a comment.
No comments yet. Be the first to share your thoughts!


